Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-105 in Advanced Solid Malignancies
NCT03642834Phase 1Completed
- Sponsor
- InnoCare Pharma
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICP-105 in solid tumor, sponsored by InnoCare Pharma. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Sep 2018; status: completed.
02
Drugs
ICP-105
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03642834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642834.